NCT02336724Unknown2 期
A Single Arm, Open Label, Multicenter, Phase II Study of Famitinib in Patients With Gastrointestinal Stromal Tumor
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 88
- 试验地点
- 1
- 主要终点
- Disease Control Rate
研究概览
简要总结
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the toxicity is manageable.
The purpose of this study is to evaluate the efficacy and safety profile of Famitinib in patients with advanced or metastatic gastrointestinal stromal tumor who failed from imatinib therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Unresectable advanced or metastatic, histologically-confirmed, gastrointestinal stromal tumor.Patients has been failed from last imatinib treatment due to disease progression or unacceptable toxicity and unable to use sunitinib.
- •At least 2 weeks since the last imatinib administration
- •Must have at least one measurable disease by RECIST1.1 criteria(tumour lesions ≥10mm in longest diameter, malignant lymph nodes ≥15mm in short axis, scanning layer ≤ 5 mm).
- •ECOG Performance status 0-1
- •Participants have adequate organ and marrow function as defined below:
- •neutrophils ≥ 1.5×10^9/L, platelets≥ 80×10^9/L, hemoglobin≥ 90g/L （no blood transfusion within 14 days), serum transaminase(ALT and AST ) ≤ 2.5×ULN (If liver metastases are present, serum transaminase≤5×ULN), total bilirubin ≤ 1.25×ULN, cholesterol ≤ 7.75mmol/L and triglyceride≤1 x ULN, creatinine ≤1x ULN,creatinine clearance rate > 50ml/min Urine protein ≥ + + and confirmed the 24-hour urinary protein>1.0 g normal serum calcium, potassium,magnesium, phosphorus INR≤1.5 and APTT≤1.5 ULN LVEF: ≥ 50%
- •Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •Prior therapy with tyrosine kinase -inhibitor agent targeting at VEGFR, PDGFR and c-Kit
- •The toxicity from previous imatinib or other treatment has not been recovered ≤ grade 1 according to CTCAE 3.0
- •Have surgery or radiotherapy within 4 weeks or have temporary radiotherapy for palliative treatment within 2 weeks
- •A variety of factors that affect the oral medication (such as inability to swallow, gastrointestinal resection, chronic diarrhea and intestinal obstruction)
- •Other cancer diagnosed within past 5 years or currently suffering , but other than cure basal cell carcinoma and cervical carcinoma in situ
- •Within 12 months before the first treatment occurs artery / venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism, etc
- •Uncontrollable thyroid dysfunction, even using medical therapy
- •Preexisting arrhythmia (including QT interval ≥ 450ms for male and 470ms for female) and ≥ grade I heart failure
- •Patients with uncontrollable hypertension after using single agent therapy (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg).
- •Known acute or chronic active hepatitis
- •Immunodeficiency: HIV positive, or other acquired immunodeficiency, congenital immunodeficiency, or organ transplantation
- •Less than 4 weeks from the last clinical trial
- •Child bearing or pregnancy female. Potential child bearing female must have a negative urine or serum pregnancy test result before initiating.
- •All subjects who are not surgically sterile or postmenopausal must agree and commit to the use of a reliable method of birth control for the duration of the study and for 6 months after the last dose of test drug.
- •Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study.
- •Mental disorders history, or Psychotropic drug abuse history
- •Abuse of Psychiatric drugs or dysphrenia
- •Other reasons from investigators' judgement
研究组 & 干预措施
Famitinib
Experimental
25 mg qd p.o.,28 days as one cycle,treatment discontinued when disease progression determined or intolerable toxicity or patients withdrawal of consent
干预措施: Famitinib (Drug)
结局指标
主要结局
Disease Control Rate
时间窗: 12 weeks
次要结局
- Overall survival(96 months)
- Progression free survival(24 months)
- Incidence of adverse events(24 months)
- Objective Response Rate(12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine TumorNCT01994213Jiangsu HengRui Medicine Co., Ltd.53
已完成
2 期
Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC)Recurrent Nasopharyngeal CarcinomaMetastatic Nasopharyngeal CarcinomaNCT01392235Jiangsu HengRui Medicine Co., Ltd.58
已完成
2 期
A Study of Famitinib in Patients With Advanced Metastatic Renal Cell CancerRenal Cell CancerMetastatic Renal Cell CancerNCT01829841Jiangsu HengRui Medicine Co., Ltd.150
暂停
2 期
A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung Cancer (NSCLC)NCT02356991Jiangsu HengRui Medicine Co., Ltd.137
已完成
2 期
A Study of Famitinib in Patients With Advanced Colorectal CancerColorectal Cancer MetastaticColorectal Cancer RecurrentColorectal CancerNCT01762293Jiangsu HengRui Medicine Co., Ltd.154